Biomarkers for cystic fi brosis drug development

@inproceedings{Muhlebach2016BiomarkersFC,
  title={Biomarkers for cystic fi brosis drug development},
  author={Marianne S Muhlebach and J P Clancy and Sonya L Heltshe and Assem Galal Ziady and T. H. Kelley and Frank Accurso and Joseph Pilewski and Nicole Mayer-Hamblett and Elizabeth G Joseloff and Scott D Sagel},
  year={2016}
}
Purpose: To provide a review of the status of biomarkers in cystic fibrosis drug development, including regulatory definitions and considerations, a summary of biomarkers in current use with supportive data, current gaps, and future needs. Methods: Biomarkers are considered across several areas of CF drug development, including cystic fibrosis transmembrane conductance regulator modulation, infection, and inflammation. Results: Sweat chloride, nasal potential difference, and intestinal current… CONTINUE READING
5
Twitter Mentions

Similar Papers

References

Publications referenced by this paper.
SHOWING 1-10 OF 117 REFERENCES

Evaluation of biomarkers and surrogate endpoints in chronic disease

BJ IoM.InMicheelCM, editor
  • Washington (DC): National Academies
  • 2010
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis.

  • Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
  • 2016

Physiologic endpoints for clinical studies for cystic fibrosis.

  • Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
  • 2016
VIEW 2 EXCERPTS